Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
6(46%)
Results Posted
25%(1 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_3
2
15%
Ph phase_1
4
31%
Ph phase_2
7
54%

Phase Distribution

4

Early Stage

7

Mid Stage

2

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
4(30.8%)
Phase 2Efficacy & side effects
7(53.8%)
Phase 3Large-scale testing
2(15.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

6

trials recruiting

Total Trials

13

all time

Status Distribution
Active(7)
Completed(4)
Terminated(1)
Other(1)

Detailed Status

Completed4
Recruiting3
Active, not recruiting3
Terminated1
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
6
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (30.8%)
Phase 27 (53.8%)
Phase 32 (15.4%)

Trials by Status

recruiting323%
active_not_recruiting323%
terminated18%
unknown18%
not_yet_recruiting18%
completed431%

Recent Activity

6 active trials
Showing 5 of 13
recruitingphase_2

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

NCT06241781
active_not_recruitingphase_2

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06492915
not_yet_recruitingphase_3

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT07445295
active_not_recruitingphase_3

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

NCT04639986
completedphase_1

Study of RP-3500, Camonsertib, in Advanced Solid Tumors

NCT04497116
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT06241781Phase 2

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

Recruiting
NCT06492915Phase 2

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Active Not Recruiting
NCT07445295Phase 3

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Not Yet Recruiting
NCT04639986Phase 3

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active Not Recruiting
NCT04497116Phase 1

Study of RP-3500, Camonsertib, in Advanced Solid Tumors

Completed
NCT06767813Phase 2

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

Recruiting
NCT04690192Phase 1

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

Completed
NCT05042128Phase 2

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Active Not Recruiting
NCT03450018Phase 1

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

Terminated
NCT05738057Phase 2

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

Recruiting
NCT03412799Phase 1

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

Completed
NCT04498689Phase 2

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Unknown
NCT01631357Phase 2

Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13